Scarica l'app Stockscreener
103.50
3.07%
3.08
Pre-mercato:
117.59
14.09
+13.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Biontech Se Adr Borsa (BNTX) Ultime notizie
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 - GlobeNewswire Inc.
BioNTech SE Sponsored ADR $BNTX Shares Acquired by HighTower Advisors LLC - Defense World
Cresset Asset Management LLC Sells 1,035 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer - The Globe and Mail
BioNTech SE Sponsored ADR $BNTX Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
BioNTech’s Promising NSCLC Study: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
BioNTech’s New PDAC Study: A Potential Game-Changer in Cancer Treatment? - The Globe and Mail
BioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer - TipRanks
Pfizer and BioNTech’s Combined Vaccine Study: A Potential Game-Changer - TipRanks
BioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
HC Wainwright Has Bearish Estimate for BioNTech Q3 Earnings - Defense World
BioNTech’s Phase II Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - MSN
US Bancorp DE Cuts Stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech (NASDAQ:BNTX) Price Target Lowered to $136.00 at HC Wainwright - Defense World
BioNTech’s BNT113 Trial: A Potential Game-Changer in Head and Neck Cancer Treatment - The Globe and Mail
BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer? - The Globe and Mail
BioNTech’s Promising Trial: BNT113 and Pembrolizumab in Head and Neck Cancer - The Globe and Mail
BioNTech’s Promising Lung Cancer Study: A Potential Game-Changer in Oncology - TipRanks
BioNTech’s New Study on Breast Cancer Treatment: A Potential Game-Changer? - TipRanks
BioNTech’s BNT327 Study: A New Hope for Lung Cancer Treatment? - The Globe and Mail
BioNTech’s Promising Phase II Study on BNT327 for Small-cell Lung Cancer - The Globe and Mail
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
BioNTech SE’s BNT331 Safety Trial: A Potential Game-Changer in Women’s Health - TipRanks
Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech ADR Earns RS Rating Upgrade - Investor's Business Daily
BioNTech’s Strategic Moves and Financial Outlook - The Globe and Mail
BioNTech SE Earnings Call: Strategic Growth Amid Challenges - TipRanks
Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech Earnings: Guidance Reiterated; Incremental Progress in Clinical Trials - Morningstar
Kylian Mbappe fires out strong message after taking iconic No. 10 shirt at Real Madrid - Goal.com
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update04.08.25News - Ariva
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - The Globe and Mail
BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday - Defense World
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - Yahoo Finance
Cancer Vaccine Market Research Service Featuring the Top 5 Developers and Pipeline Activities - GlobeNewswire Inc.
Best Momentum Stocks to Buy for July 29th - Yahoo Finance
New Strong Buy Stocks for July 29th - Yahoo Finance
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Acquired by Kestra Private Wealth Services LLC - Defense World
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'iShares U.S. Pharmaceutical ETF (ARCA:IHE), BioNTech (NASDAQ:BNTX) - Benzinga
Cerity Partners LLC Invests $357,000 in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
0.68%
1.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):